Renal complications from bisphosphonate treatment

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 3, 2012, Pages 342-347

  Hirschberg, Raimund ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Nephrotic syndrome; Renal handling of bisphosphonates

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; KIDNEY; KIDNEY DISEASE; NEPHROTIC SYNDROME; PATHOLOGY; REVIEW; RISK FACTOR;

ACUTE KIDNEY INJURY; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; KIDNEY; KIDNEY DISEASES; NEPHROTIC SYNDROME; RISK FACTORS;

EID: 84868340325     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328356062e     Document Type: Review

References (36)

1. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49:34-41.
2. Recker RR, Ste-Marie LG, Langdahl B, et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-Architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 2010; 46:660-665.
3. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373:1253-1263.
4. Z-MARK Study Group. Bone marker directed dosing ofzoledronic acid forthe prevention of skeletal complications in patients with advanced multiple myeloma. 2012; http://clinicaltrials.gov/ct2/show/study/NCT00622505. [Accessed February 5, 2012].
5. Hadji P, Gamerdinger D, Spieler W, et al. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int 2012; 23:625-633.
6. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44:551-570.
7. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacody-namics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42:1228-1236.
8. Troehler U, Bonjour JP, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int 1975; 8:6-13.
9. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone 2011; 49:42-49.
10. Weiss HM, Pfaar U, Schweitzer A, et al. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008; 36:2043-2049.
11. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010; 126:239-246.
12. Luhe A, Kunkele KP, Haiker M, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008; 22:899-909.
13. O'Sullivan TL, Akbari A, Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Ren Fail 1994; 16:767-773.
14. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acidinmultiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376:1989-1999.
15. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphospho-nate nephrotoxicity. Am J Kidney Dis 2003; 41:E18.
16. Zazgornik J, Grafinger P, Biesenbach G, et al. Acute renal failure and alendronate. Nephrol Dial Transplant 1997; 12:2797-2798.
17. Ozkurt ZN, Guliter S, Keles I, Keles H. Risedronate-induced intravascular haemolysis complicated by acute tubular necrosis. Clin Rheumatol 2005; 24:665-666.
18. Diel IJ, Weide R, Koppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 2009; 17:719-725.
19. Shah SR, Jean GW, Keisner SV, et al. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Support Care Cancer 2012; 20:87-93.
20. FDA. Zoledronic acid: renal impairment and acute renal failure. 2011; http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm167883.htm. [Accessed February 5, 2012].
21. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64:281-289.
22. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomer-ulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12:1164-1172.
23. ten Dam MA, Hilbrands LB, Wetzels JF. Nephrotic syndrome induced by pamidronate. Med Oncol 2011; 28:1196-1200.
24. Yilmaz M, Taninmis H, Kara E, et al. Nephrotic syndrome after oral bispho-sphonate (alendronate) administration in a patient with osteoporosis. Osteoporos Int 2012 [Epub ahead of print].
25. Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 2007; 22:2366-2370.
26. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
27. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
28. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100:36-43.
29. Berenson JR, Boccia R, Lopez T, et al. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). J Support Oncol 2011; 9:32-40.
30. Weide R, Koppler H, Antras L, et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 2010; 6:31-35.
31. FDA. Reclast Prescribing Information 2011; http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/021817s003lbl.pdf?utm- source¼fdaSearch&utm-medium¼website&utm- term¼Reclast prescribing information&utm- content¼1. [Accessed February 5, 2012].
32. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4:221-233.
33. Ala-Houhala I, Saha H, Liukko-Sipi S, et al. Pharmacokinetics of clodronate in haemodialysis patients. Nephrol Dial Transplant 1999; 14:699-705.
34. Bergner R, Dill K, Boerner D, Uppenkamp M. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 2002; 17:1281-1285.
35. Buttazzoni M, Rosa Diez GJ, Jager V, et al. Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 2006; 11:197-200.
36. Joffe P, Henriksen JH. Aspects of osseous, peritoneal and renal handling of bisphosphonate during peritoneal dialysis: a methodological study. Scand J Clin Lab Invest 1996; 56:327-337.